All In Biotech

Drug Trial Radar · NCT06683612

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

A Phase 1b, Open-label Study of PIPE-791 to Determine Brain and Lung Lysophosphatidic Acid Receptor 1 (LPA1) Occupancy, by [18F] PIPE-497 PET Imaging in Healthy Volunteers, Volunteers With Progressive Multiple Sclerosis, and Volunteers With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Dec 9, 2024

Primary completion

Jun 4, 2025

Study completion Jun 12, 2025

Sponsor

Lead sponsor
Contineum TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Idiopathic Pulmonary Fibrosis
  • Multiple Sclerosis
  • Multiple Sclerosis, MS
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Healthy
  • Healthy Volunteers

Interventions

  • PIPE-791Drug

    Subjects will receive a single oral dose of PIPE-791.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan.Time frame: Baseline to up to 28 days post-dose
  2. LPA1 occupancy as determined by regional total volume of distribution (VT) at each lung scan.Time frame: Baseline to up to 28 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Medicines Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.